Racial, ethnic, and language differences in screening measures for statin therapy following a major guideline change

Jorge Kaufmann, Miguel Marino, Jennifer A. Lucas, Carlos J. Rodriguez, Steffani R. Bailey, Ayana K. April-Sanders, Dave Boston, John Heintzman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Atherosclerotic cardiovascular disease (ASCVD) disproportionally affects racial and ethnic minority populations. Statin prescribing guidelines changed in 2013 to improve ASCVD prevention. It is unknown whether risk screening for statin eligibility differed across race and ethnicity over this guideline change. We examine racial/ethnic/language differences in screening measure prevalence for period-specific statin consideration using a retrospective cohort design and linked electronic health records from 635 community health centers in 24 U.S. states. Adults 50+ years, without known ASCVD, and ≥ 1 visit in 2009–2013 and/or 2014–2018 were included, grouped as: Asian, Latino, Black, or White further distinguished by language preference. Outcomes included screening measure prevalence for statin consideration, 2009–2013: low-density lipoprotein (LDL), 2014–2018: pooled cohort equation (PCE) components age, sex, race, systolic blood pressure, total cholesterol, high-density lipoprotein, smoking status. Among patients seen both periods, change in period-specific measure prevalence was assessed. Adjusting for sociodemographic and clinical factors, compared to English-preferring White patients, all other groups were more likely to have LDL documented (2009–2013, n = 195,061) and all PCE components documented (2014–2018, n = 344,504). Among patients seen in both periods (n = 128,621), all groups had lower odds of PCE components versus LDL documented in the measures' respective period; English-preferring Black adults experienced a greater decline compared to English-preferring White adults (OR 0.81; 95% CI: 0.72–0.91). Racial/ethnic/language disparities in documented screening measures that guide statin therapy for ASCVD prevention were unaffected by a major guideline change advising this practice. It is important to understand whether the newer guidelines have altered disparate prescribing and morbidity/mortality for this disease.

Original languageEnglish (US)
Article number107338
JournalPreventive medicine
StatePublished - Nov 2022


  • Cardiovascular disease
  • Disparities
  • Electronic health record
  • Minority health
  • Risk screening

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Racial, ethnic, and language differences in screening measures for statin therapy following a major guideline change'. Together they form a unique fingerprint.

Cite this